|
1
|
Laurent S and Boutouyrie P: The structural
factor of hypertension: Large and small artery alterations. Circ
Res. 116:1007–10021. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Guzik TJ and Touyz RM: Oxidative stress,
inflammation, and vascular aging in hypertension. Hypertension.
70:660–667. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shirakabe A, Ikeda Y, Sciarretta S,
Zablocki DK and Sadoshima J: Aging and autophagy in the heart. Circ
Res. 118:1563–1576. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Boraschi D, Lucchesi D, Hainzl S, Leitner
M, Maier E, Mangelberger D, Oostingh GJ, Pfaller T, Pixner C,
Posselt G, et al: IL-37: A new anti-inflammatory cytokine of the
IL-1 family. Eur Cytokine Netw. 22:127–147. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Busfield SJ, Comrack CA, Yu G, Chickering
TW, Smutko JS, Zhou H, Leiby KR, Holmgren LM, Gearing DP and Pan Y:
Identification and gene organization of three novel members of the
IL-1 family on human chromosome 2. Genomics. 66:213–216.
2000.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Dinarello CA, Nold-Petry C, Nold M, Fujita
M, Li S, Kim S and Bufler P: Suppression of innate inflammation and
immunity by interleukin-37. Eur J Immunol. 46:1067–1081.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nold-Petry CA, Lo CY, Rudloff I, Elgass
KD, Li S, Gantier MP, Lotz-Havla AS, Gersting SW, Cho SX, Lao JC,
et al: IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to
carry out its multifaceted anti-inflammatory program upon innate
signal transduction. Nat Immunol. 16:354–365. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Nold MF, Nold-Petry CA, Zepp JA, Palmer
BE, Bufler P and Dinarello CA: IL-37 is a fundamental inhibitor of
innate immunity. Nat Immunol. 11:1014–1022. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Zhuang X, Wu B, Li J, Shi H, Jin B and Luo
X: The emerging role of interleukin-37 in cardiovascular diseases.
Immun Inflamm Dis. 5:373–379. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Jia H, Liu J and Han B: Reviews of
interleukin-37: Functions, receptors, and roles in diseases. Biomed
Res Int. 2018(3058640)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ji QW, Meng K, Yu KW, Huang S, Huang Y,
Min XH, Zhong YC, Wu BW, Liu YZ, Nie SP, et al: Exogenous
interleukin 37 ameliorates atherosclerosis via inducing the Treg
response in ApoE-deficient mice. Sci Rep. 7(3310)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liu J, Lin J, He S, Wu C, Wang B, Liu J,
Duan Y, Liu T, Shan S, Yang K, et al: Transgenic overexpression of
IL-37 protects against atherosclerosis and strengthens plaque
stability. Cell Physiol Biochem. 45:1034–1050. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu T, Liu J, Lin Y, Que B, Chang C, Zhang
J, Liang Z, Gao X, Liu S, Liu L, et al: IL-37 inhibits the
maturation of dendritic cells through the IL-1R8-TLR4-NF-κB
pathway. Biochim Biophys Acta Mol Cell Biol Lipids. 1864:1338–1349.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hoeke G, Khedoe PP, van Diepen JA,
Pike-Overzet K, van de Ven B, Vazirpanah N, Mol I, Hiemstra PS,
Staal FJ, Stienstra R, et al: The effects of selective
hematopoietic expression of human IL-37 on systemic inflammation
and atherosclerosis in LDLr-deficient mice. Int J Mol Sci.
18(1672)2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhu R, Sun H, Yu K, Zhong Y, Shi H, Wei Y,
Su X, Xu W, Luo Q, Zhang F, et al: Interleukin-37 and dendritic
cells treated with interleukin-37 plus Troponin I ameliorate
cardiac remodeling after myocardial infarction. J Am Heart Assoc.
5(e004406)2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wu B, Meng K, Ji Q, Cheng M, Yu K, Zhao X,
Tony H, Liu Y, Zhou Y, Chang C, et al: Interleukin-37 ameliorates
myocardial Ischaemia/reperfusion injury in mice. Clin Exp Immunol.
176:438–451. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ji Q, Cheng G, Ma N, Huang Y, Lin Y, Zhou
Q, Que B, Dong J, Zhou Y and Nie S: Circulating Th1, Th2, and Th17
levels in hypertensive patients. Dis Markers.
2017(7146290)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Postel-Vinay N, Steichen O, Pébelier E,
Persu A, Berra E, Bobrie G, Savard S, Nogueria J and Azizi M: Home
blood pressure monitoring and e-Health: Investigation of patients'
experience with the Hy-Result system. Blood Press Monit.
25:155–161. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Rimoldi SF, Scherrer U and Messerli FH:
Secondary arterial hypertension: When, who, and how to screen? Eur
Heart J. 35:1245–1254. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ye J, Que B, Huang Y, Lin Y, Chen J, Liu
L, Shi Y, Wang Y, Wang M, Zeng T, et al: Interleukin-12p35 knockout
promotes macrophage differentiation, aggravates vascular
dysfunction, and elevates blood pressure in angiotensin II-infused
mice. Cardiovasc Res. 115:1102–1113. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yu K, Min X, Lin Y, Huang Y, Huang S, Liu
L, Peng Y, Meng K, Li D, Ji Q and Zeng Q: Increased IL-37
concentrations in patients with arterial calcification. Clin Chim
Acta. 461:19–24. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chai M, Zhang HT, Zhou YJ, Ji QW, Yang Q,
Liu YY, Zhao YX, Shi DM, Liu W, Yang LX, et al: Elevated IL-37
levels in the plasma of patients with severe coronary artery
calcification. J Geriatr Cardiol. 14:285–291. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kapelouzou A, Kontogiannis C, Tsilimigras
DI, Georgiopoulos G, Kaklamanis L, Tsourelis L and Cokkinos DV:
Differential expression patterns of toll like receptors and
interleukin-37 between calcific aortic and mitral valve cusps in
humans. Cytokine. 116:150–160. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shou X, Lin J, Xie C, Wang Y and Sun C:
Plasma IL-37 elevated in patients with chronic heart failure and
predicted major adverse cardiac events: A 1-year follow-up study.
Dis Markers. 2017(9134079)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ji Q, Zeng Q, Huang Y, Shi Y, Lin Y, Lu Z,
Meng K, Wu B, Yu K, Chai M, et al: Elevated plasma IL-37, IL-18,
and IL-18BP concentrations in patients with acute coronary
syndrome. Mediators Inflamm. 2014(165742)2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang X, Cai X, Chen L, Xu D and Li J: The
evaluation of plasma and leukocytic IL-37 expression in early
inflammation in patients with acute ST-Segment elevation myocardial
infarction after PCI. Mediators Inflamm.
2015(626934)2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yang T, Fang F, Chen Y, Ma J, Xiao Z, Zou
S, Zheng N, Yan D, Liao S, Chen S, et al: Elevated plasma
interleukin-37 playing an important role in acute coronary syndrome
through suppression of ROCK activation. Oncotarget. 8:9686–9695.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Mao X, Zhu R, Zhang F, Zhong Y, Yu K, Wei
Y, Sun H, Xu W, Luo Q, Wang Y, et al: IL-37 plays a beneficial role
in patients with acute coronary syndrome. Mediators Inflamm.
2019(9515346)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Li W, Li S, Li X, Jiang S and Han B:
Interleukin-37 elevation in patients with atrial fibrillation. Clin
Cardiol. 40:66–72. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kirabo A, Fontana V, de Faria AP, Loperena
R, Galindo CL, Wu J, Bikineyeva AT, Dikalov S, Xiao L, Chen W, et
al: DC isoketal-modified proteins activate T cells and promote
hypertension. J Clin Invest. 124:4642–4656. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
32
|
Aksit E, Gursul E, Aydin F, Samsa M and
Ozcelik F: Non-dipper hypertension is associated with slow coronary
flow among hypertensives with normal coronary angiogram. Cardiovasc
J Afr. 28:14–18. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ji Q, Meng K, Yu K, Huang S, Huang Y, Min
X, Zhong Y, Wu B, Liu Y, Nie S, et al: Exogenous interleukin 37
ameliorates atherosclerosis via inducing the Treg response in
ApoE-deficient mice. Sci Rep. 7(3310)2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chen Y, Liu JH, Zhen Z, Zuo Y, Lin Q, Liu
M, Zhao C, Wu M, Cao G, Wang R, et al: Assessment of left
ventricular function and peripheral vascular arterial stiffness in
patients with dipper and non-dipper hypertension. J Investig Med.
66:319–324. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ragot S, Herpin D, Siché JP, Ingrand P and
Mallion JM: Autonomic nervous system activity in dipper and
non-dipper essential hypertensive patients. What about sex
differences? J Hypertens. 17:1805–1811. 1999.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Di Stefano A, Caramori G, Barczyk A,
Vicari C, Brun P, Zanini A, Cappello F, Garofano E, Padovani A,
Contoli M, et al: Innate immunity but not NLRP3 inflammasome
activation correlates with severity of stable COPD. Thorax.
69:516–524. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Borzouei S, Sheikh V, Ghasemi M, Zamani A,
Telikani Z, Zareighane Z, Salehi I, Mozayanimonfared A, Amirzargar
MA and Alahgholi-Hajibehzad M: Anti-inflammatory effect of combined
sitagliptin and vitamin D3 on cytokines profile in patients with
type 2 diabetes mellitus. J Interferon Cytokine Res. 39:293–301.
2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ye J, Wang Z, Ye D, Wang Y, Wang M, Ji Q,
Huang Y, Liu L, Shi Y, Shi L, et al: Increased interleukin-11
levels are correlated with cardiac events in patients with chronic
heart failure. Mediators Inflamm. 2019(1575410)2019.PubMed/NCBI View Article : Google Scholar
|
